Smart science to improve lives™
analytical purity chromatography image
monoclonal antibody image
Croda pharma employee in a lab
vaccine development
Main image used for Virodex

Empowering biologics delivery

Unlocking future therapies

We're enabling drug delivery through high purity excipients and next generation lipids and adjuvants to tackle your solubility and stability challenges

We're developing the next generation of excipients for human and veterinary applications

Image of croda employee in lab

Products formulators love

We’re committed to investing in the next generation of excipients you need. Our teams work with you to troubleshoot formulations and develop research grade and GMP excipient solutions. Purity is our forte across our multi-compendial, GMP grade materials.

Your pharma solutions partner

circular icon of a chemical manufacturing plant

Unparalleled purity excipients

Tackle your stability challenges with unparalleled excipients of purity tailored to your needs, across all administration routes
image in circle of people working in a lab

Formulate and troubleshoot faster

Create tailored excipient solutions by working directly in partnership with our scientists to accelerate your development timelines

Regulatory expertise

Our regulatory and quality specialists are practised in supporting the use of novel and innovative excipients in a variety of formulations
Learn more about us
Image of Steve Rumbelow in the lab

Smart science to improve lives™

Your pharma solutions partner:

  • High purity excipients: Optimising the performance of formulations to solve your stability and solubility challenges
  • Vaccine adjuvants: Committed to the highest standards, with 80+ years of expertise in adjuvant research and development
  • Innovative lipids: Enabling the delivery and stability of nucleic acid-based vaccines, therapeutics and gene editing technology. 

We are committed to enabling the next generation of drug delivery systems, so by partnering with Croda Pharma, you are in safe hands.


Expert solutions for different markets:

scientist in lab looking at a slide

Human and veterinary pharmaceuticals

Our purpose, Smart science to improve lives™, is at the core of our human and veterinary market strategy. We support the pharmaceutical market by developing high purity excipients which enhance delivery, efficacy, and stability of actives. We also manufacture industry leading high purity vaccine adjuvants and innovative lipids.
Take me there
pharmacist and consumer looking at offering in a pharmacy

Consumer Health

Explore our excipients for the Consumer Health market that will aid in developing innovative products to meet changing consumer needs and market trends. Learn how we can help you grow your product brand by offering quality specialty ingredients developed for the OTC, oral hygiene, and human nutrition markets.
Take me there

Explore recent blogs:

Sohnke Voss PhD, Croda Pharma

Lipid Leaders: Söhnke Voss

In this Lipid Leaders interview, we speak to Söhnke Voss, PhD. Söhnke is a lipids expert with over 25 years’ experience in the pharmaceutical industry. Keep reading to learn more about lipids and the...

Read more
andy bright

Protein Delivery Leaders: Andrew Bright

In this Protein Delivery Leaders interview, we speak to Andrew Bright, PhD. Keep reading to learn more about breakthroughs in protein delivery and key challenges faced in biologic formulations.

Read more

Croda Pharma wins ‘Best Production/Process Development’ Award at the 17th annual Vaccine Industry Excellence awards

Croda Pharma has been awarded winner of a prestigious award for its process development for innovative ingredients, including its production of sustainably sourced Squalene to replace shark-derived...

Read more
lab image

Partnership agreement between Croda and AAHI to drive innovation in vaccine development

19 March 2024: Croda International Plc (Croda) and The Access to Advanced Health Institute (AAHI) are pleased to announce today the signing of a partnership agreement around innovation and development...

Read more